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We report a case of tacrolimus-induced transplant-associated thrombotic microangiopathies (TA-TMA) after lung transplantation.
A 71-year-old man underwent lung transplantation secondary to idiopathic pulmonary fibrosis. After 4 months, he presented 
with abdominal discomfort and dyspnea, and was diagnosed with hemolytic anemia and thrombocytopenia. Tacrolimus was con-
sidered the cause of the TMA. Tacrolimus was stopped and several sessions of plasma exchange were performed immediately 
after diagnosis of TA-TMA. However, his platelet count did not normalize, gastrointestinal bleeding was recurrent, and severe 
pneumonia developed, following which he died. TA-TMA are rare but severe, life-threatening complications in lung transplant 
recipients. Therefore, the possibility of TA-TMA should be considered in posttransplant recipients.
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FK 506 (tacrolimus) is a metabolite of the fungus Strep-
tomyces tsukubaensis with potent immunosuppressive activ-
ity and has been effective in preventing rejection of allog-
rafts of the liver, kidney, small intestine, and heart(1,2). 
This medication has many complications, including infection, 
cardiac damage, liver and kidney damage, hyperkalemia, 
and various neuropsychiatric problems such as loss of appe-
tite, insomnia, and confusion. Among them, thrombotic mi-
croangiopathies (TMAs) is a rare but severe, life-threat-
ening complication(3).
Many reports have described tacrolimus induced trans-
plant-associated TMA (TA-TMA) in solid organ or bone 
marrow transplant patients. Most cases of this complication 
have been reported in kidney transplant patients(4). Deve-
lopment of TA-TMA following lung transplantation is rare; 
therefore, we report the case of a patient who developed 
TA-TMA with severe pneumonia and gastrointestinal bleed-
ing after lung transplantation.
CASE REPORT
A 71-year-old man underwent right lung transplantation 
for idiopathic pulmonary fibrosis. He had a history of coro-
nary artery occlusive disease with hypertension and diabetes 
mellitus. His immunosuppressive regimen included tacroli-
mus, 3 mg twice a day; mycophenolate 500 mg twice a day; 
and deflazacort 9 mg twice a day with prophylactic trime-
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Fig. 1. Hemoglobin (Hb): baseline over 1 month prior to presen-
tation. Plasmapheresis was started on hospital day (HOD) 21, and 
repeated at 12 times.
Fig. 2. Platelet: baseline over 1 month prior to presentation. Pla-
smapheresis was started on hospital day (HOD) 21, and repeated 
at 12 times.
thoprim/sulfamethoxazole, itraconazole, and valganciclovir. 
His general condition was good immediately after lung 
transplantation.
At postoperative day 101, he visited the emergency de-
partment with progressively aggravating abdominal dis-
comfort and dyspnea. On physical examination, there was 
unremarkable sign except decreased skin turgor. On initial 
laboratory evaluation, hemoglobin was 10.5 g/dL, leukocyte 
was 4,090/L, and platelet was 199,000/mm3. Serum crea-
tinine was elevated (1.51 mg/dL; baseline, 0.9 mg/dL), and 
C-reactive protein was elevated at 67.4 mg/L. The liver 
function test and prothrombin and partial thromboplastin 
times were normal. Chest radiography showed mild pleural 
effusion on the right transplanted lung and diffuse reticulo-
nodular opacities combined pneumonic consolidation on the 
left lung. Initial tacrolimus level was high at ＞30.0 ng/mL. 
Esophagogastroduodenoscopy (EGD) showed gastric and 
duodenal ulcers.
By hospital day 5, leukocyte had decreased to 2,260/L, 
platelet to 51,000/L, and hemoglobin to 7.5 g/dL, indicat-
ing normocytic normochromic anemia. On hospital day 21, 
leukocyte was recovered to 7,560/L after mycophenolate 
and trimethoprim/sulfamethoxazole were stopped; however, 
anemia and thrombocytopenia persisted (hemoglobin 7.1 g/dL, 
platelet 23,000/L). Lactate dehydrogenase (LDH) had in-
creased to 2,481 IU/L, haptoglobin was markedly decreased 
to ＜10 mg/dL and reticulocyte count was elevated to 15.8%, 
suggesting hemolysis. Fibrin degradation products was 
slightly elevated to 6.14 µg/mL (normal range; 0∼5 µg/mL) 
and d-dimer was elevated to 485 ng/mL (normal range; 0∼
243 ng/mL). However serum fibrinogen, thrombin time was 
normal range, 388 mg/dL and 18 seconds, respectively. Mic-
roscopic review of the peripheral blood smear showed the 
weak positive of schistocytes and the number of nucleated 
red blood cells was elevated 18/100 white blood cell (WBC; 
normal range; 0∼2.3/100 WBC). Serum creatinine was ele-
vated to 2.17 mg/dL. The test for the enterotoxigenic Esche-
richia coli was negative. The diagnosis was TMA, which in-
cluded thrombotic thrombocytopenic purpura (TTP), hemo-
lytic uremic syndrome (HUS), and microangiopathic hemo-
lytic anemia (MAHA) associated with various systemic 
diseases. The findings were not consistent with other diag-
nosis of TMA, and other causes of TMA were not presented 
definitely; therefore, we established a diagnosis of TA-TMA 
associated with tacrolimus. We stopped tacrolimus, and plas-
mapheresis was initiated every alternate day with daily 
transfusion. After management, the laboratory findings of 
hemolysis were transiently recovered. LDH and reticulocyte 
count decreased to 545 IU/L and 2.49%, respectively. Fur-
thermore, schistocytes were not showed on peripheral blood 
smear, and hemoglobin and platelet increased to 11 g/dL 
and 44,000/L, respectively. 
However, severe infection was co-existed. Fungal pneu-
monia developed in the right lung and pneumonia in the 
96   
J Korean Soc TransplantㆍJune 2016ㆍVolume 30ㆍIssue 2
Fig. 3. Serum Lactate dehydrogenase (LDH) level: baseline over 
1 month prior to presentation. LDH elevated on hospital day (HOD)
26, then decreased by taking plasmapheresis.
left lung was aggravated. Intravenous antibiotics for bacteria 
and fungus were administered.
On hospital day 26, his blood pressure decreased to 77/48 
mmHg, and hematochezia developed. His hemoglobin de-
creased to 7.1 g/dL and platelet was 46,000/L. The finding 
of EGD showed a gastric ulcer bleeding and a duodenal 
ulcer. Although hemostasis was performed through EGD, he 
developed recurrent gastrointestinal bleeding. His hemoglo-
bin decreased to 6.1 g/dL, and platelet to 10,000/L (Figs. 
1, 2). Massive transfusion, daily plasmapheresis (total 12 
times), and repeated hemostasis via EGD were continued. 
Although LDH and reticulocyte count were recovered grad-
ually (481 IU/L and 1.21%, respectively) which showed the 
improvement of TA-TMA, the hemoglobin and platelet con-
tinuously decreased due to recurrent gastrointestinal bleeding 
(Fig. 3). Furthermore, pneumonia was not controlled and the 
general condition of patient was deteriorated. Ultimately, he 
died on hospital day 40 (postoperative day 141) due to se-
vere infection and recurrent gastrointestinal bleeding.
DISCUSSION
TMA is a syndrome that represents endothelial injury, 
microvascular thrombosis, and fibrin deposition leading to 
MAHA and thrombocytopenia due to platelet consumption. 
TMA includes TTP, HUS, and MAHA associated with vari-
ous systemic diseases or conditions including pregnancy, 
vasculitis, and other autoimmune disorders(5).
Tacrolimus is a useful immunosuppressive agent that im-
proves the survival of organ transplant recipients, but has 
many complications. Trimarchi et al.(6) reported that tacro-
limus could induce TMA through its direct and endothe-
lin-1-mediated vasoconstrictor effects on the renal vascula-
ture, leading to tissue hypoxia, endothelial cell damage, and 
deposition of platelets and fibrin in the glomeruli. However, 
the pathogenesis of tacrolimus associated TA-TMA is con-
troversial.
Development of tacrolimus induced TA-TMA can be 
life-threatening; however, if detected early, they can be 
cured. In previous reports, tacrolimus induced TMA after 
solid organ transplantation developed in 0.5% to 3% of 
transplant patients(7). Most cases have been reported in kid-
ney(6), liver(8), and bone marrow transplant recipients(9). 
However, there are few case reports in lung transplant 
patients. Myers et al.(10) reported a case of HUS in a lung 
transplant recipient receiving tacrolimus. They described 
that a 60-year-old woman with a history of lung trans-
plantation for severe chronic obstructive pulmonary disease 
developed tacrolimus-associated HUS that resolved after dis-
continuation of tacrolimus(10). Boyer et al.(11) also re-
ported that a 25-year-old woman with a history of lung 
transplantation secondary to cystic fibrosis had developed 
tacrolimus induced TA-TMA. Tacrolimus was stopped and 
replaced with cyclosporine, and complication was resolved 
with no subsequent complications(11).
A disintegrin and metalloproteinase with a thrombo-
spondin type 1 motif, member 13 (ADAMTS-13), a pro-
tease enzyme which splits ultra-large von Willebrand factor 
(vWF) multimers into smaller vWF fragments, prevents the 
entry of large multimers of vWF into the circulation(8). 
Idiopathic TTP is typically associated with ADAMTS-13 de-
ficiency resulting from inherited defect, genetic mutation, 
or the acquisition of inhibitory antibodies to ADAMTS-13(12). 
TA-TMA and TTP have similar mechanisms such as endo-
thelial damage; however, ADAMTS-13 deficiency is rarely 
observed in TA-TMA. We did not check the ADAMTS-13 
activity level in our patient; therefore, this was a limitation 
in differentiating TA-TMA from TTP in this case. 
We report an uncommon case of posttransplantation ta-
crolimus induced TA-TMA with gastrointestinal bleeding 
and severe pneumonia in a lung transplant recipient. Similar 
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to earlier studies(10,11), stopping tacrolimus plus plasma-
pheresis led to improvement of TMA; however, the patient 
died because of combined gastrointestinal bleeding and 
pneumonia.
TA-TMA is a rare but severe, life-threatening complica-
tion in lung transplant recipients; therefore, the possibility 
of TA-TMA should be considered in posttransplant reci-
pients.
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